The European Investment Bank (EIB) has provided €20 million in venture debt financing to German medical technology start-up Protembis. The company plans to use the funds to further develop ProtEmbo, a system that protects the brain during certain cardiac procedures. The device acts as a filter to prevent embolism particles from entering the arteries supplying the brain during left-sided heart surgeries and transcatheter aortic valve implantation (TAVI), reducing the risk of strokes or cognitive impairment.
This financing is part of the InvestEU program, which aims to stimulate additional investment in new technologies across Europe. Protembis aims to protect patients from serious complications with their innovative technology, developed in Europe.
Protembis’ ProtEmbo system has also received funding through a Series B financing round and is undergoing clinical trials to demonstrate its superiority over existing products. The device is inserted through the left wrist and covers the upper vessel wall of the aortic arch to protect the brain from particles during TAVI procedures.
The system aims to provide a simple, reliable solution to prevent brain injuries during cardiac procedures, ultimately improving patient outcomes and reducing healthcare costs associated with such complications. Protembis is dedicated to the health and well-being of people in Europe and is working towards advancing their innovative technology to benefit patients worldwide.
Source
Photo credit worldbusinessoutlook.com